Oncology-focused digital therapeutics firm Mika Well being introduced a partnership with pharma corporations AstraZeneca and Daiichi Sankyo for an initiative dubbed “UNITE” to supply digital therapeutics to girls present process breast most cancers remedies.
Mika Well being’s app provides most cancers sufferers entry to psychological help to scale back disease-related nervousness, melancholy and stress. Sufferers can observe uncomfortable side effects from medicines, obtain treatment reminders, receive training and diet recommendation, and coordinate appointments.
The digital therapeutic, already licensed as a medical gadget and launched within the EU, will be personalised to a person’s particular kind of most cancers.
By the partnership, Mika Well being’s choices will likely be used alongside pharmaceutical remedy.
German-speaking sufferers in Switzerland can first entry the providing, after which the businesses will increase to incorporate Switzerland’s French- and Italian-speaking areas.
“Digital therapies have gotten more and more necessary in fashionable most cancers therapy,” Adam Nosal, head of oncology at AstraZeneca Switzerland, stated in a press release. “This partnership with Mika permits us to increase entry to holistic most cancers care and achieve insights that can form our broader efforts to enhance therapeutic choices for most cancers sufferers.”
THE LARGER TREND
In June, Mika Well being and the worldwide nonprofit Most cancers Help Group introduced they’ll present an AI-enabled oncology-focused digital therapeutic for U.S.-based most cancers sufferers and their caregivers to entry psychological well being and different help providers freed from cost.
Earlier this 12 months, the corporate introduced a partnership with AI oncology agency Large Bio to supply free entry to Miko’s choices by way of Large Bio’s platform.
Mika sufferers would even be given the power to take part in Large’s AI-enabled biomarker testing and scientific trial matching choices.
The HIMSS AI in Healthcare Discussion board is scheduled to happen September 5-6 in Boston. Study extra and register.
